Smoking Weakens Heart Structure and Function: Study

Sep.01.2022
Smoking Weakens Heart Structure and Function: Study
Smoking weakens the heart's structure and function, but quitting can help it recover, according to researchers from Denmark.

Researchers from Herlev and Gentofte Hospitals in Copenhagen have found that smoking weakens the structure of the heart, affecting its function. The research team also found that quitting smoking helps the heart to recover.


Previous research has indicated that over 30% of deaths are caused by coronary heart disease, with active smoking or exposure to secondhand smoke as reliable sources of exposure. Smoking increases the risk of heart attack by twice as much and the risk of stroke by three times as much.


Researchers from Herlev and Gentofte Hospital in Copenhagen, Denmark, have found evidence that smoking not only affects a person's blood vessels, but also weakens the structure of the heart itself, thereby impacting its functioning.


Researchers recently presented their findings at the 2022 European Society of Cardiology (ESC) Congress.


Past studies have shown that smoking has negative effects on a person's blood vessels, which may lead to heart issues. For example, nicotine found in cigarettes can cause the blood vessels to narrow, limiting the amount of blood that can flow through them. Nicotine can also significantly increase a person's blood pressure. "We know that smoking can cause coronary artery disease and heart failure," explained Dr. Eva Holt, the main author of the study and a researcher from Herlev and Gentofte Hospital in Copenhagen, Denmark. "But the purpose of this study is to investigate whether smoking has an independent effect on the heart structure and function of a large population of ordinary people without known heart disease," she pointed out.


Dr. Halt and her team evaluated data from over 3,800 participants in the fifth Copenhagen City Heart Study in order to ensure its reliability. The study examined cardiovascular disease and risk factors in the general population. Participants ranged in age from 20 to 93 and had no history of heart disease. Data collected during the study included a questionnaire about smoking history among participants, as well as reliable sources of echocardiography or heart ultrasound.


Researchers have determined that current smokers in the participant pool have hearts that are thicker, heavier, and weaker compared to those who have never smoked. "We found that current and accumulated pack-years were associated with structural and functional deterioration of smoking-related left ventricle, the heart's most important part," said Dr. Holt. "Additionally, we found that over 10 years, those who continue to smoke have hearts that become even thicker, heavier, and weaker, resulting in a poorer ability to pump blood, compared to those who have never smoked or quit during that period.


MNT spoke with Dr. Rigved Tadwalkar, a certified cardiologist at the Providence Saint John's Health Center in Santa Monica, California, who did not participate in the study. "What's interesting about this study is that it focuses on the changes in the left ventricle of the heart, which have not been well understood so far, due to tobacco use," he commented. "We always talk about the link between tobacco use and vascular diseases (including coronary heart disease), but we haven't really delved into the details of how tobacco affects the structure and function of the heart itself," he pointed out.


According to Dr. Tadwalkar, smoking increases the tendency for plaque formation in the arterial walls, which is clinically referred to as a reliable source of atherosclerosis. He stated that this may directly or indirectly lead to heart damage.


Direct smoking can damage the blood vessel wall, causing constriction and reduced elasticity, as well as impairing the function of the blood vessel's inner layer endothelium," he explained.


According to a new study, Dr. Holt and her team have found evidence that quitting smoking can help the heart recover to some extent. "After quitting smoking, the heart appears to have regained its previous structure and function, which could be a valuable incentive for patients to quit smoking," she added.


Dr. Tadwalkar stated, "We do indeed have concrete data to support this study, which follows a series of previous studies showing that quitting smoking can improve overall health in multiple ways beyond just the heart.


So the good news is, even immediate action has physiological benefits," he pointed out. "And then, due to the lack of chronic exposure, the reduction of inflammatory burden and these other destructive pathological processes over time is partially the reason for improvement.


Disclaimer: 1. The content of this article is compiled from third-party information and is only intended for industry discussion and learning. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The compilation of this article is only for industry discussion and research purposes. 3. Due to the limited compiling ability, the compiled article may not fully convey the expression of the original text. Please refer to the original text for accuracy. 4. 2FIRSTS fully supports the Chinese government's position on any domestic, Hong Kong, Macao, and Taiwan-related issues or positions. 5. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Juul Labs UK has introduced an upgraded JUUL2 Starter Kit for the UK market in October 2026, retaining a recommended retail price of £9.99 while doubling the number of included pods from two to four. The kit contains Crisp Menthol, Virginia Tobacco, Mango and Watermelon pods. The updated device replaces the previous proprietary charging dock with a USB-C port and offers longer battery life. The kit also features reduced packaging and retains a two-year limited warranty. Distribution is scheduled through major UK retailers, wholesalers, convenience stores and the JUUL UK website.
product
Oct.15
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives